['progressive metastatic prostate cancer']
['enzalutamide', 'placebo']

        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the prostate without neuroendocrine
             differentiation or small cell features

          -  Ongoing androgen deprivation therapy with a GnRH analogue or bilateral orchiectomy

          -  Progressive disease despite androgen deprivation therapy as defined by rising PSA
             levels or progressive soft tissue or bone disease

          -  No prior treatment with cytotoxic chemotherapy

          -  Asymptomatic or mildly symptomatic from prostate cancer

        Exclusion Criteria:

          -  Severe concurrent disease, infection, or co-morbidity that, in the judgment of the
             Investigator, would make the patient inappropriate for enrollment

          -  Known or suspected brain metastasis or active leptomeningeal disease

          -  History of another malignancy within the previous 5 years other than curatively
             treated non-melanomatous skin cancer

          -  History of seizure including febrile seizure or any condition that may predispose to
             seizure (e.g., prior stroke, brain arteriovenous malformation, head trauma with loss
             of consciousness requiring hospitalization).
      